Zacks Investment Research Lowers ZEALAND PHARMA/S (NASDAQ:ZEAL) to Sell

ZEALAND PHARMA/S (NASDAQ:ZEAL) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Saturday, reports.

According to Zacks, “Zealand Pharma A/S is a biotechnology company. It focused on the discovery, design and development of peptide-based medicines. Zealand Pharma A/S is based in Copenhagen, Denmark. “

ZEAL has been the topic of several other research reports. Needham & Company LLC set a $32.00 target price on ZEALAND PHARMA/S and gave the company a “buy” rating in a research note on Wednesday, September 18th. Morgan Stanley increased their target price on ZEALAND PHARMA/S from $29.00 to $30.00 and gave the company an “overweight” rating in a research note on Monday, August 19th. Guggenheim initiated coverage on ZEALAND PHARMA/S in a research note on Thursday, September 19th. They issued a “buy” rating on the stock. TheStreet lowered ZEALAND PHARMA/S from a “c” rating to a “d+” rating in a research note on Friday, August 16th. Finally, ValuEngine lowered ZEALAND PHARMA/S from a “hold” rating to a “sell” rating in a research report on Wednesday, October 2nd. Two analysts have rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $27.33.

NASDAQ:ZEAL traded down $0.42 during mid-day trading on Friday, hitting $23.04. The company had a trading volume of 544 shares, compared to its average volume of 9,453. ZEALAND PHARMA/S has a fifty-two week low of $11.51 and a fifty-two week high of $28.85. The business’s fifty day moving average is $23.11 and its two-hundred day moving average is $21.31. The firm has a market cap of $746.50 million, a P/E ratio of 7.68 and a beta of 2.05.

ZEALAND PHARMA/S (NASDAQ:ZEAL) last released its earnings results on Thursday, August 15th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.10). The business had revenue of $3.00 million during the quarter, compared to analysts’ expectations of $7.50 million. As a group, research analysts anticipate that ZEALAND PHARMA/S will post -2.76 earnings per share for the current year.

A hedge fund recently bought a new stake in ZEALAND PHARMA/S stock. Susquehanna International Group LLP purchased a new position in shares of ZEALAND PHARMA/S (NASDAQ:ZEAL) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 15,348 shares of the company’s stock, valued at approximately $331,000. Hedge funds and other institutional investors own 9.07% of the company’s stock.


Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua.

Featured Article: Cost of Goods Sold (COGS)

Get a free copy of the Zacks research report on ZEALAND PHARMA/S (ZEAL)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for ZEALAND PHARMA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZEALAND PHARMA/S and related companies with's FREE daily email newsletter.